Table 4.
Case‐only analysis: weighted genetic risk scores and prostate cancer stage and grade (PRACTICAL consortium)
| Outcome | Localized/low grade (n) | Advanced/high grade (n) | ORa | 95% CI | P value |
|---|---|---|---|---|---|
| LDL score | |||||
| Advanced versus localized | 13,707 | 4301 | 0.91 | 0.51, 1.64 | 0.77 |
| High grade versus low grade | 9237 | 8515 | 1.50 | 0.92, 2.46 | 0.11 |
| HDL score | |||||
| Advanced versus localized | 13,707 | 4301 | 1.02 | 0.74, 1.39 | 0.92 |
| High grade versus low grade | 9237 | 8515 | 1.03 | 0.79, 1.34 | 0.82 |
| TG score | |||||
| Advanced versus localized | 13,707 | 4301 | 1.68 | 0.95, 3.00 | 0.08 |
| High grade versus low grade | 9237 | 8515 | 0.93 | 0.57, 1.52 | 0.77 |
Advanced (T3 to T4 or SEER staging regional or distant), localized (T1 to T2 or SEER staging localized), high grade (Gleason ≥7), low grade (Gleason ≤6).
LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; TG, triglyceride; OR, odds ratio.
a
Per unit increase in genetic risk score (SD trait), adjusted for top eight principal components (higher LDL/TG scores reflect increasing circulating LDL/TG, higher HDL scores reflect lower circulating HDL).